Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years

GlaxoSmithKline1 site in 1 country130 target enrollmentSeptember 8, 2009

ConditionsInfluenza

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Influenza
Sponsor: GlaxoSmithKline
Enrollment: 130
Locations: 1
Primary Endpoint: Number of Seroprotected Subjects for HI Antibodies
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.

Registry

clinicaltrials.gov

Start Date

September 8, 2009

End Date

September 28, 2010

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A male or female aged 18 to 60 years at the time of the first vaccination.
•Subjects who the investigator believes that they can and will comply with the requirements of the protocol
•Written informed consent obtained from the subject.
•Satisfactory baseline medical assessment by history and physical examination. Stable health status is defined as the absence of health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within one month prior to enrollment.
•Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or multiple-user device.
•Female subjects of non-childbearing potential may be enrolled in the study.
•Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
•Female subjects of childbearing potential may be enrolled in the study, if the subject:
•has practiced adequate contraception for 30 days prior to vaccination, and
•has a negative pregnancy test on the day of vaccination, and

Exclusion Criteria

•Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period. Potential subjects in the follow-up phase of a prior investigational study may be enrolled if the investigator's judgment is that it will have no effect on safety, reactogenicity, or immunogenicity endpoints in this study, and that it does not violate the protocol requirements of the prior trial.
•Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
•Presence of an axillary temperature \>= 37.5°C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination. NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved, vaccination occurs within the window specified by the protocol, and all other eligibility criteria continue to be satisfied.
•Diagnosed with cancer, or treatment for cancer, within the past 3 years.
•Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.
•Persons with a history of histological-confirmed basal cell carcinoma of the skin successfully treated with local excisions only are excepted and may enroll within 3 years of diagnosis, but other histological types of skin cancer require a 3-year untreated and disease-free window as above.
•Women who are disease free 3 years or more after the treatment for breast cancer and receiving long-term prophylactic tamoxifen are excepted and may enroll.
•Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
•Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
•Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period.

Outcomes

Primary Outcomes

Number of Seroprotected Subjects for HI Antibodies

Time Frame: At Day 42

A seroprotected subject was defined as a vaccinated subject with a serum hemagglutination inhibition (HI) titer ≥ 1:40. The flu strain assessed was A/California/7/2009 (H1N1)v-like influenza (Flu A/CAL/7/09).

Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies

Time Frame: At Day 42

Seroconversion was defined as: For initially seronegative subjects \[antibody titer below (\<) 1:10 prior to vaccination\], antibody titer greater than or equal to (≥) 1:40 after vaccination; For initially seropositive subjects (antibody titer ≥ 1:10 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was A/California/7/2009 (H1N1)v-like influenza (Flu A/CAL/7/09).

Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease

Time Frame: At Day 42

GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI geometric mean titers (GMTs) post-vaccination compared to pre-vaccination. The flu strain assessed was Flu A/CAL/7/09.

Secondary Outcomes

Number of Subjects With HI Antibody Concentrations Above the Cut-off Value(At Day 364)
Titers for Serum HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease(At Day 364)
Number of Seroconverted Subjects for HI Antibodies(At Day 364)
Number of Seroprotected Subjects for HI Antibodies(At Day 364)
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease(At Day 364)
Number of Days With Solicited General Symptoms(During the 7-day (Days 0-6) post-vaccination period following each dose and across doses)
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)(Within 21 days after the first vaccination and 63 days after the second vaccination (Day 0 - Day 20 and Day 21 - Day 83))
Number of Subjects With Adverse Events of Specific Interest (AESIs)(During the entire study period (from Day 0 up to Day 364))
Titers for Serum Neutralizing Antibodies Against Flu A/Neth/602/09 Strain of Influenza Disease(At Days 0, 21 and 42)
Number of Seroconverted Subjects for Serum Neutralizing Antibodies Against Flu A/Neth/602/09(At Days 21 and 42)
Number of Days With Solicited Local Symptoms(During the 7-day (Days 0-6) post-vaccination period following each dose and across doses)
Number of Subjects With Serious Adverse Events (SAEs)(During the entire study period (from Day 0 up to Day 364))
Number of Subjects With Any and Grade 3 Solicited Local Symptoms(During the 7-day (Days 0-6) post-vaccination period following each dose and across doses)
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(During the 7-day (Days 0-6) post-vaccination period following each dose and across doses)